PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Shares Bought by BML Capital Management LLC

BML Capital Management LLC boosted its position in shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP - Free Report) by 105.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,466,684 shares of the company's stock after acquiring an additional 1,777,912 shares during the period. PMV Pharmaceuticals accounts for 3.3% of BML Capital Management LLC's holdings, making the stock its 11th biggest position. BML Capital Management LLC owned 6.70% of PMV Pharmaceuticals worth $5,235,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Virtu Financial LLC acquired a new stake in shares of PMV Pharmaceuticals in the 3rd quarter worth $42,000. M&T Bank Corp raised its stake in PMV Pharmaceuticals by 54.6% in the third quarter. M&T Bank Corp now owns 399,548 shares of the company's stock valued at $596,000 after buying an additional 141,064 shares during the last quarter. Peapod Lane Capital LLC acquired a new stake in PMV Pharmaceuticals in the fourth quarter worth about $673,000. PFM Health Sciences LP grew its stake in shares of PMV Pharmaceuticals by 57.7% during the third quarter. PFM Health Sciences LP now owns 2,011,040 shares of the company's stock worth $2,996,000 after acquiring an additional 735,578 shares during the last quarter. Finally, Sio Capital Management LLC grew its stake in shares of PMV Pharmaceuticals by 18.7% during the third quarter. Sio Capital Management LLC now owns 3,214,239 shares of the company's stock worth $4,789,000 after acquiring an additional 505,831 shares during the last quarter. 90.20% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

PMV Pharmaceuticals Stock Up 2.5 %

Shares of PMV Pharmaceuticals stock traded up $0.03 during midday trading on Tuesday, hitting $1.25. The company had a trading volume of 71,848 shares, compared to its average volume of 143,471. The company has a fifty day simple moving average of $1.41 and a 200 day simple moving average of $1.51. The stock has a market cap of $64.92 million, a price-to-earnings ratio of -1.25 and a beta of 1.45. PMV Pharmaceuticals, Inc. has a 12-month low of $1.20 and a 12-month high of $2.26.

PMV Pharmaceuticals (NASDAQ:PMVP - Get Free Report) last posted its quarterly earnings results on Monday, March 3rd. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.08). As a group, analysts expect that PMV Pharmaceuticals, Inc. will post -1.06 EPS for the current year.

PMV Pharmaceuticals Company Profile

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.